BioCentury | Nov 7, 2018
Company News

Management tracks: Myovant, Alkahest

...was VP of external science and innovation at Allergan plc (NYSE:AGN). Progressive kidney disease company Xortx...
...Inc. (CSE:XRX; OTCQB:XRTXF) hired James Fairbairn as CFO. He succeeds Dave Matthews, who was named Xortx...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...NYSE:PFE) Bosulif bosutinib Dual inhibitor of BCR-ABL tyrosine kinase (BCR-ABL) and Src PKD Phase II Xortx Pharma Corp....
Items per page:
1 - 2 of 2
BioCentury | Nov 7, 2018
Company News

Management tracks: Myovant, Alkahest

...was VP of external science and innovation at Allergan plc (NYSE:AGN). Progressive kidney disease company Xortx...
...Inc. (CSE:XRX; OTCQB:XRTXF) hired James Fairbairn as CFO. He succeeds Dave Matthews, who was named Xortx...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...NYSE:PFE) Bosulif bosutinib Dual inhibitor of BCR-ABL tyrosine kinase (BCR-ABL) and Src PKD Phase II Xortx Pharma Corp....
Items per page:
1 - 2 of 2